Systemic Absorption of Budesonide Nasal Irrigation
Budesonide mixed with saline for nasal irrigation has minimal systemic absorption and does not cause clinically significant adrenal suppression, making it safe for long-term use in chronic rhinosinusitis management.
Key Pharmacokinetic Properties
Budesonide undergoes extensive first-pass hepatic metabolism (85-95%) of any swallowed drug, with metabolites having low potency 1. This explains why the therapeutic effects are primarily local rather than systemic, even when higher concentrations are used in nasal irrigations compared to standard sprays 1.
Evidence on Systemic Absorption
Direct Measurement Studies
The most relevant research directly measured budesonide levels and cortisol response:
No adrenal suppression detected: A study using 0.5 mg budesonide in 240 mL saline twice daily for 6 weeks showed serum cortisol levels remained normal (12.8 ± 3.5 mcg/dL post-treatment vs 9.8 ± 5.4 mcg/dL baseline), and 24-hour urinary cortisol also stayed within normal ranges 2.
No detectable plasma budesonide: When comparing mucosal atomization device (MAD) versus nasal irrigation, neither delivery method produced significant plasma budesonide levels, and ACTH stimulation testing showed no adrenal suppression in either group 3.
Recent meta-analysis confirms safety: A 2025 meta-analysis of 1,464 patients found pooled mean serum cortisol levels remained within normal range after budesonide nasal irrigation, with no significant difference in intraocular pressure compared to saline-only irrigation 4.
Actual Retained Dose
A 2024 study quantified that only 37.9% of administered budesonide (approximately 0.17 mg from a 0.5 mg dose) is actually retained in the sinonasal cavity after high-volume irrigation, with the remainder expelled in the effluent 5. This retained dose decreases further with time post-surgery (27.4% retention at >3 months post-ESS) 5.
Clinical Guideline Perspective
The 2025 American Academy of Otolaryngology guidelines acknowledge that long-term topical nasal steroid use has not been shown to impact systemic cortisol levels, contribute to nasal mucosal atrophy, or increase ocular complications 6. However, they note the lack of FDA approval for intranasal steroid irrigations and recommend their use primarily in select post-endoscopic surgery patients with moderate to severe disease not controlled by standard sprays 6.
Important Caveats
Pediatric considerations: While FDA data shows most children maintain intact HPA axis response, some younger children (6 months-2 years) showed declines in ACTH-stimulated cortisol, though not statistically significant 1. This data is from nebulized budesonide for asthma, not nasal irrigation, but warrants caution.
Individual monitoring: Despite overall safety, patients on long-term therapy should have individualized assessment for ophthalmic monitoring based on clinical judgment 6.
Off-label use: This remains an off-label application without standardized protocols for concentration, volume, or frequency 6.
Bottom Line
The combination of extensive first-pass metabolism, low retained dose (only ~38% of administered drug), and multiple studies showing normal cortisol levels makes budesonide nasal irrigation remarkably safe from a systemic absorption standpoint. The therapeutic benefit is achieved through high local concentrations at the sinonasal mucosa rather than systemic effects 1, 2, 3, 4.